Two aceclidine formulations show promise in phase 2 trial for presbyopia treatment
Click Here to Manage Email Alerts
Lenz Therapeutics reported positive topline data from the phase 2 INSIGHT clinical trial investigating LNZ100 and LNZ101 for the treatment of presbyopia.
LNZ100 (aceclidine) and LNZ101 (aceclidine plus brimonidine) both met the trial’s primary endpoint of near visual acuity improvement of three lines or greater without losing one line or more in distance visual acuity at 1 hour. Seventy-one percent of patients treated with LNZ100 and 56% of patients treated with LNZ101 met this endpoint compared with 6% of patients treated with vehicle, according to a press release.
Source: Adobe Stock.
Additionally, 37% of patients treated with LNZ100 and 48% of patients treated with LNZ101 maintained a three-line or greater improvement compared with vehicle for all time points, including at the last measurement at 10 hours.
Both treatments maintained an average pupil size of 1.5 mm to 2 mm for 10 hours, a biomarker of efficacy. LNZ100 and LNZ101 were well tolerated with no serious drug-related adverse events reported.
“We know that the majority of presbyopia patients are looking for a product that is highly effective in improving near vision for their full workday,” Eef Schimmelpennink, president and CEO of Lenz, said in the release. “Our best-in-class results clearly reflect this ideal profile, with 10-hour efficacy, and further extend our potential for category leadership.”
Lenz plans to initiate phase 3 trials based on these positive data.
Read more about
Click Here to Manage Email Alerts